









Markets
/
Stocks
/
nasdaq-mrk
/

Merck & Co Inc

MRK

116.370USD

+0.690+0.60%

Close 03/24, 16:00（ET）Quotes delayed by 15 min

354.00BMarket Cap

15.95P/E TTM



Merck & Co Inc

116.370

+0.690+0.60%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Merck & Co Inc

Currency: USD Updated: 2026-03-24

Key Insights

Merck & Co Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 127.84.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Merck & Co Inc's Score

Industry at a Glance

Industry Ranking

20 / 157

Overall Ranking

77 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

49°C



Very Low

Very High

Positive

Merck & Co Inc Highlights

StrengthsRisks

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 65.01B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.

Fairly Valued

The company’s latest PE is 15.95, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.99B shares, decreasing 2.78% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 51.41K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.02.

Analyst Rating

Based on 32 analysts

Buy

Current Rating

127.837

Target Price

+11.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of Merck & Co Inc is 8.61, ranking 38 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 16.40B, representing a year-over-year increase of 4.97%, while its net profit experienced a year-over-year increase of 20.84%.

Score

Industry at a Glance

Previous score

8.61

Change



Financials

6.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Merck & Co Inc's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of Merck & Co Inc is 8.17, ranking 27 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 15.95, which is 5650.00% below the recent high of 917.15 and 33.18% above the recent low of 10.66.

Score

Industry at a Glance

Previous score

8.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 20/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of Merck & Co Inc is 7.75, ranking 96 out of 157 in the Pharmaceuticals industry. The average price target is 102.50, with a high of 139.00 and a low of 82.00.

Score

Industry at a Glance

Previous score

7.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 32 analysts

Buy

Current Rating

127.837

Target Price

+11.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Merck & Co Inc

MRK

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of Merck & Co Inc is 6.91, ranking 42 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 123.43 and the support level at 111.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.76

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.823

Sell

RSI(14)

49.462

Neutral

STOCH(KDJ)(9,3,3)

54.987

Buy

ATR(14)

2.599

Low Volatility

CCI(14)

-0.780

Neutral

Williams %R

46.363

Neutral

TRIX(12,20)

-0.135

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

114.986

Buy

MA10

115.396

Buy

MA20

117.356

Sell

MA50

115.864

Buy

MA100

107.142

Buy

MA200

95.018

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Merck & Co Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 80.26%, representing a quarter-over-quarter decrease of 1.35%. The largest institutional shareholder is The Vanguard, holding a total of 253.10M shares, representing 10.24% of shares outstanding, with 2.25% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

250.94M

-0.32%

BlackRock Institutional Trust Company, N.A.

141.15M

-1.15%

State Street Investment Management (US)

118.18M

-0.26%

Wellington Management Company, LLP

75.28M

-2.05%

Geode Capital Management, L.L.C.

59.80M

+1.44%

Charles Schwab Investment Management, Inc.

53.70M

-0.31%

Norges Bank Investment Management (NBIM)

36.11M

+3.23%

Fidelity Management & Research Company LLC

27.61M

-3.04%

Fisher Investments

Star Investors

24.07M

-3.78%

BlackRock Asset Management Ireland Limited

22.50M

-1.24%

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Merck & Co Inc is 9.20, ranking 13 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Merck & Co Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.